Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 14-04-2023 | Gastric Cancer | Review

The role of Pcdh10 in neurological disease and cancer

Authors: Yilan Zhen, Macarena Pavez, Xinying Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2023

Abstract

Background

Protocadherin 10 (PCDH 10), a member of the superfamily of protocadherins, is a Ca2⁺-dependent homophilic cell-cell adhesion molecule expressed on the surface of cell membranes. Protocadherin 10 plays a critical role in the central nervous system including in cell adhesion, formation and maintenance of neural circuits and synapses, regulation of actin assembly, cognitive function and tumor suppression. Additionally, Pcdh10 can serve as a non-invasive diagnostic and prognostic indicator for various cancers.

Methods

This paper collects and reviews relevant literature in Pubmed.

Conclusion

This review describes the latest research understanding the role of Pcdh10 in neurological disease and human cancer, highlighting the importance of scrutinizing its properties for the development of targeted therapies and identifying a need for further research to explore Pcdh10 functions in other pathways, cell types and human pathologies.

Aoki E, Kimura R, Suzuki ST, Hirano S (2003) Distribution of OL-protocadherin protein in correlation with specific neural compartments and local circuits in the postnatal mouse brain. Neuroscience 117(3):593–614. https://doi.org/10.1016/s0306-4522(02)00944-2CrossRefPubMed

Bertrand KC, Mack SC, Northcott PA, Garzia L, Dubuc A, Pfister SM et al (2011) PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Childs Nerv Syst 27(8):1243–1249. https://doi.org/10.1007/s00381-011-1486-xCrossRefPubMed

Bhat S, Kabekkodu SP, Varghese VK, Chakrabarty S, Mallya SP, Rotti H et al (2017) Aberrant gene-specific DNA methylation signature analysis in cervical cancer. Tumour Biol 39(3):1010428317694573. https://doi.org/10.1177/1010428317694573CrossRefPubMed

Bing Y, Tian M, Li G, Jiang B, Ma Z, Li L et al (2018) Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patients. Medicine (Baltimore) 97(35):e12055. https://doi.org/10.1097/MD.0000000000012055CrossRefPubMed

Bocchio M, Nabavi S, Capogna M (2017) Synaptic plasticity, engrams, and network oscillations in amygdala circuits for storage and retrieval of emotional memories. Neuron 94(4):731–743. https://doi.org/10.1016/j.neuron.2017.03.022CrossRefPubMed

Bodea CA, Middleton FA, Melhem NM, Klei L, Song Y, Tiobech J et al (2017) Analysis of shared haplotypes amongst palauans maps loci for psychotic disorders to 4q28 and 5q23-q31. Mol Neuropsychiatry 2(4):173–184. https://doi.org/10.1159/000450726CrossRefPubMed

Bucan M, Abrahams BS, Wang K, Glessner JT, Herman EI, Sonnenblick LI et al (2009) Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet 5(6):e1000536. https://doi.org/10.1371/journal.pgen.1000536CrossRefPubMedPubMedCentral

Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A et al (2019) BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci. https://doi.org/10.3390/ijms20215369CrossRefPubMedPubMedCentral

Curia MC, Fantini F, Lattanzio R, Tavano F, Di Mola F, Piantelli M et al (2019) High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma. BMC Cancer 19(1):452. https://doi.org/10.1186/s12885-019-5616-2CrossRefPubMedPubMedCentral

Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL et al (2013) Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer 109(3):807–813. https://doi.org/10.1038/bjc.2013.351CrossRefPubMedPubMedCentral

Deng J, Liang H, Ying G, Dong Q, Zhang L, Yu J et al (2014) Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer. J Am Coll Surg 219(5):904–913. https://doi.org/10.1016/j.jamcollsurg.2014.06.014CrossRefPubMed

Deng QK, Lei YG, Lin YL, Ma JG, Li WP (2016) Prognostic value of protocadherin10 (PCDH10) methylation in serum of prostate cancer patients. Med Sci Monit 22:516–521. https://doi.org/10.12659/msm.897179CrossRefPubMedPubMedCentral

Ding K, Su Y, Pang L, Lu Q, Wang Z, Zhang S et al (2009) Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells. Carcinogenesis 30(1):35–42. https://doi.org/10.1093/carcin/bgn251CrossRefPubMed

Dobre M, Salvi A, Pelisenco IA, Vasilescu F, De Petro G, Herlea V et al (2021) Crosstalk between DNA methylation and gene mutations in colorectal cancer. Front Oncol 11:697409. https://doi.org/10.3389/fonc.2021.697409CrossRefPubMedPubMedCentral

Echizen K, Nakada M, Hayashi T, Sabit H, Furuta T, Nakai M et al (2014) PCDH10 is required for the tumorigenicity of glioblastoma cells. Biochem Biophys Res Commun 444(1):13–18. https://doi.org/10.1016/j.bbrc.2013.12.138CrossRefPubMed

Fang S, Huang SF, Cao J, Wen YA, Zhang LP, Ren GS (2013) Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression. Clin Exp Med 13(2):127–134. https://doi.org/10.1007/s10238-012-0182-9CrossRefPubMed

Ferri SL, Dow HC, Schoch H, Lee JY, Brodkin ES, Abel T (2021) Age- and sex-specific fear conditioning deficits in mice lacking Pcdh10, an autism associated gene. Neurobiol Learn Mem 178:107364. https://doi.org/10.1016/j.nlm.2020.107364CrossRefPubMed

Flaherty E, Maniatis T (2020) The role of clustered protocadherins in neurodevelopment and neuropsychiatric diseases. Curr Opin Genet Dev 65:144–150. https://doi.org/10.1016/j.gde.2020.05.041CrossRefPubMedPubMedCentral

Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P et al (2014) De novo mutations in schizophrenia implicate synaptic networks. Nature 506(7487):179–184. https://doi.org/10.1038/nature12929CrossRefPubMedPubMedCentral

Goncalves NP, Martins D, Saraiva MJ (2016) Overexpression of protocadherin-10 in transthyretin-related familial amyloidotic polyneuropathy. Am J Pathol 186(7):1913–1924. https://doi.org/10.1016/j.ajpath.2016.02.020CrossRefPubMed

Halbleib JM, Nelson WJ (2006) Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 20(23):3199–3214. https://doi.org/10.1101/gad.1486806CrossRefPubMed

Harada H, Miyamoto K, Yamashita Y, Taniyama K, Mihara K, Nishimura M et al (2015) Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer. Cancer Med 4(10):1536–1546. https://doi.org/10.1002/cam4.507CrossRefPubMedPubMedCentral

Heidarzadeh S, Motalleb GH, Zorriehzahra MJ (2019) Evaluation of tumor regulatory genes and apoptotic pathways in the cytotoxic effect of cytochalasin H on malignant human glioma cell line (U87MG). Cell J 21(1):62–69. https://doi.org/10.22074/cellj.2019.5948CrossRefPubMed

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weissenbacher B et al (2014) Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. Mod Pathol 27(6):906–915. https://doi.org/10.1038/modpathol.2013.204CrossRefPubMed

Hirano S, Yan Q, Suzuki ST (1999) Expression of a novel protocadherin, OL-protocadherin, in a subset of functional systems of the developing mouse brain. J Neurosci 19(3):995–1005. https://doi.org/10.1523/JNEUROSCI.19-03-00995.1999CrossRefPubMedPubMedCentral

Homayouni R, Rice DS, Curran T (2001) Disabled-1 interacts with a novel developmentally regulated protocadherin. Biochem Biophys Res Commun 289(2):539–547. https://doi.org/10.1006/bbrc.2001.5998CrossRefPubMed

Hoshina N, Johnson-Venkatesh EM, Rally VR, Sant J, Hoshina M, Seiglie MP et al (2022) ASD/OCD-linked protocadherin-10 regulates synapse, but not axon, development in the amygdala and contributes to fear- and anxiety-related behaviors. J Neurosci 42(21):4250–4266. https://doi.org/10.1523/JNEUROSCI.1843-21.2022CrossRefPubMedPubMedCentral

Hou YC, Deng JY, Zhang RP, Xie XM, Cui JL, Wu WP et al (2015) Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer. Cancer Biomark 15(5):567–573. https://doi.org/10.3233/CBM-150496CrossRefPubMed

Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22(44):9694–9705. https://doi.org/10.3748/wjg.v22.i44.9694CrossRefPubMedPubMedCentral

Jao TM, Tsai MH, Lio HY, Weng WT, Chen CC, Tzeng ST et al (2014) Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis. Int J Cancer 135(11):2593–2603. https://doi.org/10.1002/ijc.28899CrossRefPubMed

Jao TM, Fang WH, Ciou SC, Yu SL, Hung YL, Weng WT et al (2021) PCDH10 exerts tumor-suppressor functions through modulation of EGFR/AKT axis in colorectal cancer. Cancer Lett 499:290–300. https://doi.org/10.1016/j.canlet.2020.11.017CrossRefPubMed

Kahr I, Vandepoele K, van Roy F (2013) Delta-protocadherins in health and disease. Prog Mol Biol Transl Sci 116:169–192. https://doi.org/10.1016/B978-0-12-394311-8.00008-XCrossRefPubMed

Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388(10039):73–85. https://doi.org/10.1016/S0140-6736(16)00141-0CrossRefPubMed

Kim SY, Chung HS, Sun W, Kim H (2007) Spatiotemporal expression pattern of non-clustered protocadherin family members in the developing rat brain. Neuroscience 147(4):996–1021. https://doi.org/10.1016/j.neuroscience.2007.03.052CrossRefPubMed

Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H (2011) Non-clustered protocadherin. Cell Adh Migr 5(2):97–105. https://doi.org/10.4161/cam.5.2.14374CrossRefPubMedPubMedCentral

Kleinberger I, Sanders E, Staes K, Van Troys M, Hirano S, Hochepied T et al (2022) Innovative mouse models for the tumor suppressor activity of Protocadherin-10 isoforms. BMC Cancer 22(1):451. https://doi.org/10.1186/s12885-022-09381-yCrossRefPubMedPubMedCentral

Li Z, Li W, Xie J, Wang Y, Tang A, Li X et al (2011) Epigenetic inactivation of PCDH10 in human prostate cancer cell lines. Cell Biol Int 35(7):671–676. https://doi.org/10.1042/CBI20100568CrossRefPubMed

Li Y, Yang ZS, Song JJ, Liu Q, Chen JB (2012a) Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma. Int J Mol Med 29(4):704–710. https://doi.org/10.3892/ijmm.2012.880CrossRefPubMedPubMedCentral

Li Z, Chim JC, Yang M, Ye J, Wong BC, Qiao L (2012b) Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta 1823(2):298–305. https://doi.org/10.1016/j.bbamcr.2011.11.011CrossRefPubMed

Li Z, Yang Z, Peng X, Li Y, Liu Q, Chen J (2014) Nuclear factor-kappaB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma. Mol Med Rep 10(2):832–838. https://doi.org/10.3892/mmr.2014.2285CrossRefPubMed

Light SEW, Jontes JD (2017) Delta-protocadherins: organizers of neural circuit assembly. Semin Cell Dev Biol 69:83–90. https://doi.org/10.1016/j.semcdb.2017.07.037CrossRefPubMedPubMedCentral

Lin CJ, Lai HC, Wang KH, Hsiung CA, Liu HW, Ding DC et al (2011) Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. Am J Obstet Gynecol 204(1):21 e21-27. https://doi.org/10.1016/j.ajog.2010.07.036CrossRef

Lin YL, Li ZG, He ZK, Guan TY, Ma JG (2012) Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. J Int Med Res 40(6):2117–2123. https://doi.org/10.1177/030006051204000609CrossRefPubMed

Lin YL, Li ZG, Guan TY (2013) The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma. Urol Int 90(2):219–224. https://doi.org/10.1159/000345053CrossRefPubMed

Liu L, Chen F, Xiu A, Du B, Ai H, Xie W (2018a) Identification of key candidate genes and pathways in endometrial cancer by integrated bioinformatical analysis. Asian Pac J Cancer Prev 19(4):969–975. https://doi.org/10.22034/APJCP.2018.19.4.969CrossRefPubMedPubMedCentral

Liu W, Wu J, Shi G, Yue X, Liu D, Zhang Q (2018b) Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer. Oncol Lett 16(4):4462–4470. https://doi.org/10.3892/ol.2018.9214CrossRefPubMedPubMedCentral

Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS et al (2008) Identifying autism loci and genes by tracing recent shared ancestry. Science 321(5886):218–223. https://doi.org/10.1126/science.1157657CrossRefPubMedPubMedCentral

Nakao S, Platek A, Hirano S, Takeichi M (2008) Contact-dependent promotion of cell migration by the OL-protocadherin-Nap1 interaction. J Cell Biol 182(2):395–410. https://doi.org/10.1083/jcb.200802069CrossRefPubMedPubMedCentral

Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH, Loke SL et al (2009) Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer 48(11):983–992. https://doi.org/10.1002/gcc.20703CrossRefPubMedPubMedCentral

Narayan G, Xie D, Freddy AJ, Ishdorj G, Do C, Satwani P et al (2013) PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer 52(11):1030–1041. https://doi.org/10.1002/gcc.22098CrossRefPubMed

Pancho A, Aerts T, Mitsogiannis MD, Seuntjens E (2020) Protocadherins at the crossroad of signaling pathways. Front Mol Neurosci 13:117. https://doi.org/10.3389/fnmol.2020.00117CrossRefPubMedPubMedCentral

Pimson C, Ekalaksananan T, Pientong C, Promthet S, Putthanachote N, Suwanrungruang K et al (2016) Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer. PeerJ 4:e2112. https://doi.org/10.7717/peerj.2112CrossRefPubMedPubMedCentral

Port RG, Gajewski C, Krizman E, Dow HC, Hirano S, Brodkin ES et al (2017) Protocadherin 10 alters gamma oscillations, amino acid levels, and their coupling; baclofen partially restores these oscillatory deficits. Neurobiol Dis 108:324–338. https://doi.org/10.1016/j.nbd.2017.08.013CrossRefPubMed

Qi Y, Ooi HS, Wu J, Chen J, Zhang X, Tan S et al (2016) MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10. Oncotarget 7(11):12693–12703. https://doi.org/10.18632/oncotarget.7281CrossRefPubMedPubMedCentral

Qin H, Samuels JF, Wang Y, Zhu Y, Grados MA, Riddle MA et al (2016) Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry 21(2):270–276. https://doi.org/10.1038/mp.2015.32CrossRefPubMed

Qiu C, Bu X, Jiang Z (2016) Protocadherin-10 acts as a tumor suppressor gene, and is frequently downregulated by promoter methylation in pancreatic cancer cells. Oncol Rep 36(1):383–389. https://doi.org/10.3892/or.2016.4793CrossRefPubMed

Roberson-Nay R, Lapato DM, Wolen AR, Lancaster EE, Webb BT, Verhulst B et al (2020) An epigenome-wide association study of early-onset major depression in monozygotic twins. Transl Psychiatry 10(1):301. https://doi.org/10.1038/s41398-020-00984-2CrossRefPubMedPubMedCentral

Salmeron-Barcenas EG, Illades-Aguiar B, Del Moral-Hernandez O, Ortega-Soto A, Hernandez-Sotelo D (2019) HOTAIR knockdown decreased the activity Wnt/beta-catenin signaling pathway and increased the mRNA levels of its negative regulators in hela cells. Cell Physiol Biochem 53(6):948–960. https://doi.org/10.33594/000000188CrossRefPubMed

Schneider BG, Mera R, Piazuelo MB, Bravo JC, Zabaleta J, Delgado AG et al (2015) DNA methylation predicts progression of human gastric lesions. Cancer Epidemiol Biomark Prev 24(10):1607–1613. https://doi.org/10.1158/1055-9965.EPI-15-0388CrossRef

Schoch H, Kreibich AS, Ferri SL, White RS, Bohorquez D, Banerjee A et al (2017) Sociability deficits and altered amygdala circuits in mice lacking Pcdh10, an autism associated gene. Biol Psychiatry 81(3):193–202. https://doi.org/10.1016/j.biopsych.2016.06.008CrossRefPubMed

Seo SI, Yoon JH, Byun HJ, Lee SK (2021) HOTAIR induces methylation of PCDH10, a tumor suppressor gene, by regulating DNMT1 and sponging with miR-148b in gastric adenocarcinoma. Yonsei Med J 62(2):118–128. https://doi.org/10.3349/ymj.2021.62.2.118CrossRefPubMedPubMedCentral

Silva TD, Vidigal VM, Felipe AV, Jacqueline Miranda DEL, Neto RA, Saad SS et al (2013) DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett 6(6):1687–1692. https://doi.org/10.3892/ol.2013.1606CrossRefPubMedPubMedCentral

Skuja E, Butane D, Nakazawa-Miklasevica M, Daneberga Z, Purkalne G, Miklasevics E (2019) Deletions in metastatic colorectal cancer with chromothripsis. Exp Oncol 41(4):323–327. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13841CrossRefPubMed

Tanaka N, Huttenhower C, Nosho K, Baba Y, Shima K, Quackenbush J et al (2010) Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol 177(6):2731–2740. https://doi.org/10.2353/ajpath.2010.100361CrossRefPubMedPubMedCentral

Tang X, Yin X, Xiang T, Li H, Li F, Chen L et al (2012) Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark 12(1):11–19. https://doi.org/10.3233/CBM-2012-00280CrossRefPubMed

Tang J, Chen X, Cai B, Chen G (2019) A logical relationship for schizophrenia, bipolar, and major depressive disorder. Part 4: evidence from chromosome 4 high-density association screen. J Comp Neurol 527(2):392–405. https://doi.org/10.1002/cne.24543CrossRefPubMed

Tsai NP, Wilkerson JR, Guo W, Maksimova MA, DeMartino GN, Cowan CW et al (2012) Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell 151(7):1581–1594. https://doi.org/10.1016/j.cell.2012.11.040CrossRefPubMedPubMedCentral

Uemura M, Nakao S, Suzuki ST, Takeichi M, Hirano S (2007) OL-protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat Neurosci 10(9):1151–1159. https://doi.org/10.1038/nn1960CrossRefPubMed

Wang KH, Liu HW, Lin SR, Ding DC, Chu TY (2009) Field methylation silencing of the protocadherin 10 gene in cervical carcinogenesis as a potential specific diagnostic test from cervical scrapings. Cancer Sci 100(11):2175–2180. https://doi.org/10.1111/j.1349-7006.2009.01285.xCrossRefPubMed

Wang L, Xie PG, Lin YL, Ma JG, Li WP (2014) Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy. Med Sci Monit 20:1363–1368. https://doi.org/10.12659/MSM.891241CrossRefPubMedPubMedCentral

Wang X, Dou N, Wang J, Zhang Y, Li Y, Gao Y (2021) FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes. Int J Biol Sci 17(4):915–925. https://doi.org/10.7150/ijbs.56733CrossRefPubMedPubMedCentral

Williams EO, Sickles HM, Dooley AL, Palumbos S, Bisogni AJ, Lin DM (2011) Delta protocadherin 10 is regulated by activity in the mouse main olfactory system. Front Neural Circ 5:9. https://doi.org/10.3389/fncir.2011.00009CrossRef

Wolverton T, Lalande M (2001) Identification and characterization of three members of a novel subclass of protocadherins. Genomics 76(1–3):66–72. https://doi.org/10.1006/geno.2001.6592CrossRefPubMed

Xiaolei T, Jiang M, Yang N, Jing Z (2022) Effects of EZH2 on invasion and migration of endometrial stromal cells in endometriosis patients by regulating PCDH10 gene H3K27 methylation. Altern Ther Health Med 29:42–49

Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q et al (2015) PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/beta-catenin/BCL-9 signaling pathway. Oncol Rep 34(2):747–754. https://doi.org/10.3892/or.2015.4056CrossRefPubMed

Xu M, Liu C, Pu L, Lai J, Li J, Ning Q et al (2021) Systemic analysis of the expression levels and prognosis of breast cancer-related cadherins. Exp Biol Med (maywood) 246(15):1706–1720. https://doi.org/10.1177/15353702211010417CrossRefPubMed

Yang Y, Jiang Y, Jiang M, Zhang J, Yang B, She Y et al (2016) Protocadherin 10 inhibits cell proliferation and induces apoptosis via regulation of DEP domain containing 1 in endometrial endometrioid carcinoma. Exp Mol Pathol 100(2):344–352. https://doi.org/10.1016/j.yexmp.2016.03.002CrossRefPubMed

Yang J, Hou C, Wang H, Perez EA, Do-Umehara HC, Dong H et al (2022) Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10. Cancer Lett 555:216025. https://doi.org/10.1016/j.canlet.2022.216025CrossRefPubMed

Ye M, Li J, Gong J (2017) PCDH10 gene inhibits cell proliferation and induces cell apoptosis by inhibiting the PI3K/Akt signaling pathway in hepatocellular carcinoma cells. Oncol Rep 37(6):3167–3174. https://doi.org/10.3892/or.2017.5630CrossRefPubMedPubMedCentral

Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW et al (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25(7):1070–1080. https://doi.org/10.1038/sj.onc.1209154CrossRefPubMed

Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H et al (2009) Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136(2):640-651 e641. https://doi.org/10.1053/j.gastro.2008.10.050CrossRefPubMed

Yu B, Yang H, Zhang C, Wu Q, Shao Y, Zhang J et al (2010) High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. Neoplasma 57(3):247–252. https://doi.org/10.4149/neo_2010_03_247CrossRefPubMed

Zhang S, Qiu M, Gao S, Tian T (2021) Circular RNA PCDH10 regulates the tumorigenesis of pancreatic cancer through the miR-338-3p/hTERT axis. Am J Transl Res 13(4):2181–2197PubMedPubMedCentral

Zhao Y, Yang Y, Trovik J, Sun K, Zhou L, Jiang P et al (2014) A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer Res 74(18):5103–5117. https://doi.org/10.1158/0008-5472.CAN-14-0427CrossRefPubMed

Zhao Y, Yang Y, Trovik J, Sun K, Zhou L, Jiang P et al (2019) Novel PCDH10-Wnt-MALAT1 regulatory axis in endometrioid endometrial adenocarcinoma. Hong Kong Med J 25(Suppl 7(5)):17–22PubMed

Zhong X, Zhu Y, Mao J, Zhang J, Zheng S (2013) Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer. J Cancer Res Clin Oncol 139(3):485–490. https://doi.org/10.1007/s00432-012-1353-5CrossRefPubMed

Zhong X, Shen H, Mao J, Zhang J, Han W (2017) Epigenetic silencing of protocadherin 10 in colorectal cancer. Oncol Lett 13(4):2449–2453. https://doi.org/10.3892/ol.2017.5733CrossRefPubMedPubMedCentral

Zhou LN, Hua X, Deng WQ, Wu QN, Mei H, Chen B (2015) PCDH10 interacts with hTERT and negatively regulates telomerase activity. Medicine (Baltimore) 94(50):e2230. https://doi.org/10.1097/MD.0000000000002230CrossRefPubMed

Zhou J, Wang L, Sun Q, Chen R, Zhang C, Yang P et al (2021) Hsa_circ_0001666 suppresses the progression of colorectal cancer through the miR-576–5p/PCDH10 axis. Clin Transl Med 11(11):e565. https://doi.org/10.1002/ctm2.565CrossRefPubMedPubMedCentral

Title: The role of Pcdh10 in neurological disease and cancer
Authors: Yilan Zhen
Macarena Pavez
Xinying Li
Publication date: 14-04-2023
Publisher: Springer Berlin Heidelberg
Keywords: Gastric Cancer
Gastric Cancer
Pancreatic Cancer
Pancreatic Cancer
Colorectal Cancer
Colorectal Cancer
Epigenetics
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-04743-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2023

Development of 177Lu-Cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugate

Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment

Correction to: Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma

Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer

Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery

Cancer immune escape: the role of antigen presentation machinery

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials